Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.36 |
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185975 | 0.97 | TDP1 (0.44) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL2868438 | 0.95 | TDP1 (0.42) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| Nitrogen SCHEMBL10935733 | 0.91 | ALDH1A1 (0.39) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL21793456 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL5641724 | 0.79 | ALDH1A1 (0.43) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL1367532 | 0.77 | TDP1 (0.44) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL10717781 | 0.76 | MEN1 (0.38) | TDP1ALDH1A1TSHRTP53POLB | |
| SCHEMBL11620553 | 0.75 | TDP1 (0.42) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| Hydrochloric Acid SCHEMBL2855745 | 0.75 | TDP1 (0.42) | TDP1ALDH1A1TSHRCYP1A2CYP2A6 | |
| SCHEMBL516025 | 0.75 | ALDH1A1 (0.48) | TDP1ALDH1A1TSHRTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2037951-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | Sirion Therapeutics, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007150046-A2 | METHODS AND COMPOSITIONS FOR TREATING OPHTHALMIC CONDITIONS VIA MODULATION OF MEGALIN ACTIVITY | SIRION THERAPEUTICS, INC (US) | 2007-12-27 | — | — | WO | disclosed |